Become a Member

Eli Lilly and Company (LLY)

Healthcare • Drug Manufacturers - General

48
Beobachten
$1.044,13
Price
+0,67%
Change
936,02 Mrd. $
Market Cap
-
P/E Ratio

Neumann-Score Stock Analysis

48
out of 100
Beobachten
Valuation??/100
Profitability??/100
Growth??/100

Unlock Score Details

Become a member and get access to all analyses.

Become a Member

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyv ...

CEO
David A. Ricks
Employees
47.000
Country
US